Clinical Characteristics and Disease Progression Among Non-Diabetic APOL1-Mediated Kidney Disease Patients and Patients with Other CKD
Kidney360 · 2026
DOI: 10.34067/kid.0000001097 ↗Kurz gefasst
Fachartikel in der Zeitschrift Kidney360, 2026. Verfasst von Ankit Shah und 6 weiteren Autor:innen. Beteiligte Einrichtung: Vertex Pharmaceuticals Incorporated, Boston, Massachusetts. Hauptthemen laut MEDLINE: Renal Insufficiency, Chronic, Apolipoprotein L1. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Vertex Pharmaceuticals.
Abstract (Originalsprache)
Background
Apolipoprotein L1 ( APOL1 )-mediated kidney disease (AMKD) is an aggressive form of chronic kidney disease (CKD). This study described characteristics of non-diabetic patients with AMKD and compared their disease progression to non-diabetic patients with other forms of CKD.
Methods
This retrospective study used clinical and biosample data from NashBio (Nashbio contains electronic health records (EHR) generated during clinical encounters at Vanderbilt University Medical Center (VUMC)). Non-diabetic patients with ≥ 1 CKD diagnosis code who were ≥10 years of age at index (date of first CKD diagnosis code in patient’s medical record) were included. The AMKD and other forms of CKD cohorts were defined based on the presence of APOL1 risk alleles and then their clinical and demographic characteristics were described. To assess progression patients were matched 1:1 on gender, presence of hypertension, and CKD stage at index and were followed until the last observation in the data. Progression outcomes including time from index to dialysis, kidney transplant, and diagnosis of CKD requiring kidney replacement therapy were assessed using Kaplan-Meier analysis, with log-rank tests used to compare matched cohorts.
Results
The study included 645 patients with AMKD and 6,749 patients with other forms of CKD. AMKD patients were significantly younger than other CKD patients (median 44.0 vs. 61.0 years; p
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Vertex Pharmaceuticals Incorporated, Boston, Massachusetts.
- Analysis Group, Inc., Boston, Massachusetts.
ORCID-Profile: Manish Maski, Debbie Goldschmidt, Ogo Egbuna, Ashley Holub
Förderung
- Vertex Pharmaceuticals
Zitieren
APA
Shah, A., Maski, M., Goldschmidt, D., Egbuna, O., Holub, A., Swallow, E., & Barber, B. (2026). Clinical Characteristics and Disease Progression Among Non-Diabetic APOL1-Mediated Kidney Disease Patients and Patients with Other CKD. Kidney360. https://doi.org/10.34067/kid.0000001097
Vancouver
Shah A, Maski M, Goldschmidt D, Egbuna O, Holub A, Swallow E, et al. Clinical Characteristics and Disease Progression Among Non-Diabetic APOL1-Mediated Kidney Disease Patients and Patients with Other CKD. Kidney360. 2026. doi:10.34067/kid.0000001097
BibTeX
@article{Shah2026,
author = {Shah, Ankit and Maski, Manish and Goldschmidt, Debbie and Egbuna, Ogo and Holub, Ashley and Swallow, Elyse and Barber, Beth},
title = {Clinical Characteristics and Disease Progression Among Non-Diabetic APOL1-Mediated Kidney Disease Patients and Patients with Other CKD},
journal = {Kidney360},
year = {2026},
doi = {10.34067/kid.0000001097}
}
EUVIMED